Axial Spondyloarthritis | Disease Landscape and Forecast | G7 | 2025
The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: TNF-alpha inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira, Johnson & Johnson Innovative Medicine’s Remicade and Simponi / Simponi Aria, and UCB’s Cimzia) and IL-17 inhibitors (Novartis’s Cosentyx and Eli Lilly’s Taltz). TNF-alpha inhibitors are the most prescribed biologics for AxSpA that is refractory to NSAIDs, but branded TNF-alpha inhibitors face competition from the cost-effective biosimilars and the growing IL-17 class. In 2019, the FDA approved Cimzia for nonradiographic (nr)-AxSpA, the first FDA approval for this subpopulation, followed by both IL-17 inhibitors in June 2020 and AbbVie’s Rinvoq in October 2022. The approval of novel oral targeted therapies—JAK inhibitors (Rinvoq and Pfizer’s Xeljanz)—for ankylosing spondylitis and the recent approval of an additional IL-17 inhibitor (UCB’s Bimzelx) for AxSpA will only heighten the competition and further reshape the treatment of this disease.
Questions answered:
- How large is the treatable AxSpA population, and how will diagnosis / drug-treatment rates change over time?
- What are the interviewed experts’ insights on current treatment options for AS and nr-AxSpA? What clinical needs remain unfulfilled?
- What pipeline products are the most promising, and what key therapies are in early-phase development?
- What are the interviewed experts’ opinions of the use of Bimzelx, Xeljanz and Rinvoq for AS? What sales / uptake could JAK inhibitors secure in AxSpA?
- What are the drivers of and constraints in the AxSpA therapy market, and how will the market evolve over the forecast period?
Content highlights:
Geographies: United States, EU5, Japan
Primary research: 34 country-specific interviews with thought-leading rheumatologists; supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalent cases of AxSpA by country; AS and nr-AxSpA subpopulations.
Forecast: 10-year, annualized, drug-level sales and patient share of key AxSpA therapies through 2034, segmented by brands / generics and epidemiological subpopulations
Drug treatments: Coverage of key current and late-phase emerging therapies
Product description: Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events.
